By identifying the cancer drivers and elucidating the genetic landscape of HCC, we will be able to understand how tumor heterogeneity may affect, and possibly confound, targeted therapeutic interventions, such as HER2 amplification in breast cancer cases [128]. This evidence concerns the gene ERBB2 and breast cancer.